Advertisement

Osteoporosis International

, Volume 25, Issue 9, pp 2263–2269 | Cite as

Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection

  • T. Porcelli
  • D. Gotti
  • A. Cristiano
  • F. Maffezzoni
  • G. Mazziotti
  • E. Focà
  • F. Castelli
  • A. Giustina
  • E. Quiros-Roldan
Original Article

Abstract

Summary

This study investigated the bone of HIV patients both in terms of quantity and quality. It was found that HIV-infected patients did fracture independently of the degree of bone demineralization as in other forms of secondary osteoporosis.

Introduction

We aimed to determine the prevalence of vertebral fractures (VFs) in HIV patients who were screened by bone mineral density (BMD) and to explore possible factors associated with VFs.

Methods

This is a cross-sectional study that included HIV-infected patients recruited in the Clinic of Infectious and Tropical Diseases and that underwent BMD measurement by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip (Lunar Prodigy, GE Healthcare). For the assessment of VFs, anteroposterior and lateral X-ray examinations of the thoracic and lumbar spines were performed and were centrally digitized. Logistic regression models were used in the statistical analysis of factors associated with VFs.

Results

One hundred thirty-one consecutive patients with HIV infection (93 M, 38 F, median age 51 years; range, 36-75) underwent BMD measurement: 25.2 % of patients showed normal BMD, while 45 % were osteopenic and 29.7 % osteoporotic. Prevalence of low BMD (osteopenia and osteoporosis) was higher in females as compared to males (90 vs 69 %) with no significant correlation with age and body mass index. VFs occurred more frequently in patients with low BMD as compared to patients with normal BMD (88.5 vs. 11.4 %; p < 0.001) without any significant difference between osteopenia and osteoporosis (43 vs. 46 %; p = 0.073). VFs were significantly associated with older age and previous AIDS events.

Conclusions

These results suggest a BMD <−1 threshold to identify patients at risk of skeletal fragility and, therefore, good candidates for morphometric evaluation of spine X-ray in line with other forms of secondary osteoporosis with impaired bone quality.

Keywords

Antiretroviral therapy HIV Osteoporosis Vertebral fracture 

Notes

Conflicts of interest

None.

References

  1. 1.
    Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617–623PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E et al (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402–409PubMedCrossRefGoogle Scholar
  3. 3.
    Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L et al (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24:2827–2833PubMedCrossRefGoogle Scholar
  4. 4.
    Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917–1923PubMedCrossRefGoogle Scholar
  5. 5.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N et al (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22:395–402PubMedCrossRefGoogle Scholar
  6. 6.
    Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al (2001) Reduced bone mineral density in HIV-positive individuals. AIDS 15:1731–1733PubMedCrossRefGoogle Scholar
  8. 8.
    Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807–808PubMedCrossRefGoogle Scholar
  9. 9.
    Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S et al (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38:893–897PubMedCrossRefGoogle Scholar
  10. 10.
    Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174PubMedCrossRefGoogle Scholar
  11. 11.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 65:191–197CrossRefGoogle Scholar
  12. 12.
    Jacobson DL, Spiegelman D, Knox TK, Wilson IB (2008) Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49:298–308PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B et al (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6:e17217PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Briot K, Kolta S, Flandre P, Boue F, Van Ngo P, Cohen-Codar I et al (2011) Prospective one-year bone loss in treatment-naive HIVR men and women on single or multiple drug HIV therapies. Bone 48:1133–1139PubMedCrossRefGoogle Scholar
  15. 15.
    Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL et al (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817–824PubMedCrossRefGoogle Scholar
  16. 16.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191–201PubMedCrossRefGoogle Scholar
  17. 17.
    Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9:89–95PubMedCrossRefGoogle Scholar
  18. 18.
    Van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE et al (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23:1367–1376PubMedCrossRefGoogle Scholar
  19. 19.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P et al (2011) Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2007) Bone mineral density remains stable in HAART treated HIV-infected men over 2 years. Clin Endocrinol 67:270–275CrossRefGoogle Scholar
  21. 21.
    Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490PubMedCrossRefGoogle Scholar
  22. 22.
    Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275–1280PubMedCrossRefGoogle Scholar
  23. 23.
    Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRefGoogle Scholar
  24. 24.
    Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM, Fordham JN et al (2008) Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11:188–206PubMedCrossRefGoogle Scholar
  25. 25.
    Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42:39–51PubMedCrossRefGoogle Scholar
  26. 26.
    McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS et al (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51:937–946PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205:S391–S398PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Torti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D et al (2012) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517PubMedCrossRefGoogle Scholar
  29. 29.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRefGoogle Scholar
  30. 30.
    European AIDS Clinical Society (2013) Prevention and management of non-infectious comorbidities in HIV. Version 7.0. http://eacsociety.org/Guidelines.aspx. Accessed 17 Jul 2014)
  31. 31.
    Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D et al (2012) The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol 77:672–678CrossRefGoogle Scholar
  32. 32.
    Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41:58–69PubMedCrossRefGoogle Scholar
  33. 33.
    Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368–1375PubMedCrossRefGoogle Scholar
  34. 34.
    Mazziotti G, Bianchi A, Bonadonna S et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93:4649–4655PubMedCrossRefGoogle Scholar
  35. 35.
    Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259PubMedCrossRefGoogle Scholar
  36. 36.
    Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRefGoogle Scholar
  37. 37.
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRefGoogle Scholar
  38. 38.
    Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20PubMedCrossRefGoogle Scholar
  39. 39.
    Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39:288–293PubMedCrossRefGoogle Scholar
  40. 40.
    Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402–3410PubMedCrossRefGoogle Scholar
  41. 41.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
  42. 42.
    Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRefGoogle Scholar
  43. 43.
    Wanner DP, Tyndall A, Walker UA (2009) Tenofovir-induced osteomalacia. Clin Exp Rheumatol 27:1001–1003PubMedGoogle Scholar
  44. 44.
    Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57:1483–1488PubMedCrossRefGoogle Scholar
  45. 45.
    Brown TT (2013) HIV: an under-recognized secondary cause of osteoporosis? J Bone Miner Res 28:1256–1258PubMedCrossRefGoogle Scholar
  46. 46.
    Maffezzoni F, Porcelli T, Karamouzis I et al (2014) Osteoporosis in human immunodeficiency virus patients—an emerging clinical concern. Eur Endocrinol 10:79–83Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2014

Authors and Affiliations

  • T. Porcelli
    • 1
  • D. Gotti
    • 2
  • A. Cristiano
    • 1
  • F. Maffezzoni
    • 1
  • G. Mazziotti
    • 1
  • E. Focà
    • 2
  • F. Castelli
    • 2
  • A. Giustina
    • 1
  • E. Quiros-Roldan
    • 2
  1. 1.Chair of EndocrinologyUniversity of BresciaBresciaItaly
  2. 2.Division of Infectious and Tropical DiseasesUniversity of BresciaBresciaItaly

Personalised recommendations